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ABSTRACT
Objective: To compare the efficacy and tolerance of single-dose grepafloxacin with cefixime for
treatment of uncomplicated gonorrhea in women.
Methods: Women attending nine sexually-transmitted-disease clinics in the United States who
had suspected uncomplicated gonorrhea were enrolled in an open study. Participants were ran-
domized to receive single oral doses of grepafloxacin (400 mg) or cefixime (400 mg), and efficacy
was evaluated in those who returned for follow-up assessment 5 to 10 days later. The primary
measure of efficacy was microbiological response to therapy as determined by pre- and posttreat-
ment culture results for Neisseria gonorrhoeae.
Results: Of 380 patients enrolled, 124 in the grepafloxacin group and 131 in the cefixime group
were evaluated for microbiological response. Cervical gonococcal infections were eradicated in 99%
of patients in both treatment groups, with only one persistent infection in each group. All pharyn-
geal (n 15) and rectal (n 32) gonococcal infections treated with grepafloxacin were cured,
whereas 5 of 16 (31%) pharyngeal and 1 of 38 (3%) rectal infections failed to respond to cefixime.
Although a third (123 of 386) of N. gonorrhoeae pretreatment isolates were resistant to penicillin or
tetracycline, this had no impact on cure rates. Both drugs were well tolerated, with vaginitis being
the most common treatment-related adverse event in each group.
Conclusions: This study shows that single-dose grepafloxacin is at least as effective as cefixime for
treating women with uncomplicated cervical gonorrhea. Grepafloxacin also appears to be highly
effective against extragenital infections. Infect. Dis. Obstet. Gynecol. 5:370-375, 1997.
(C) 1998 Wiley-Liss, Inc.
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espite a decline of gonorrhea in the United
States during the past two decades, this sexu-
ally transmitted disease (STD) remains common in
many inner cities, and some rural areas are cur-
rently experiencing high rates of infection,z Treat-
ment of gonorrhea involved the almost exclusive
use of penicillin and tetracyclines from the 1940s
until the mid-1980s, when antibiotic resistance be-
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came troublesome.3 Today there are numerous an-
timicrobial agents at our disposal that are highly
active against Neisseria gonorrhoeae, making the
choice of treatment more difficult. All of the com-
mercially available fluoroquinolones have proved
effective as single-dose therapy of gonorrhea,4, s
including infections due to penicillinase-producing
gonococci, 5 but only ciprofloxacin, ofloxacin,
enoxacin, and norfloxacin are among the agents
currently recommended by the Centers for Disease
Control and Prevention.6 After initial treatment for
gonorrhea, follow-up therapy with an antibiotic
regimen effective against possible coexistent infec-
tion with Chlamydia trachomatis is recommended.6
Thus, the ideal antibiotic would be one that is ef-
fective against both gonococcal and chlamydial in-
fections.
Grepafloxacin is a new, orally administered fluo-
roquinolone with excellent in vitro activity against
N. gonorrhoeae; it is 4-8 fold more potent than
ofloxacin against penicillin- and tetracycline-
resistant strains7 and more active than ofloxacin
against C. trachomatis. 8 The drug is concentrated
intracellularly,9 has a long serum half-life (--12
hours) that allows for once-daily dosing,1 and
achieves high therapeutic levels in male and fe-
male genital tissue. TM lZ These features indicate
that grepafloxacin is a promising agent for treating
common STDs.
A recent study has shown that a single 400-mg
dose of grepafloxacin was as effective as the same
dose of cefixime in the treatment of gonococcal
urethritis in men. 13 The purpose of the present
multicenter study was to investigate the efficacy
and tolerance of grepafloxacin and cefixime in
women with uncomplicated gonorrhea.
SUBJECTS AND METHODS
The patients studied were recruited at nine public
clinics for STDs in the United States between June
1993 and February 1995. The study sites were
Druid STD Clinic, Baltimore, MD; Jefferson
County Health Department STD Clinic, Birming-
ham, AL; Boston City Hospital STD Clinic, Bos-
ton, MA; Kings County Hospital Center STD
Clinic, Brooklyn NY; Disease Control Service,
Denver, CO; Bell Flower Clinic, Indianapolis, IN;
Louisiana State University, Section of Infectious
Diseases, Department of Medicine, New Orleans,
LA; City and County of San Francisco, Depart-
ment of Public Health, San Francisco, CA; and
Harborview Medical Center STD Clinic, Seattle,
WA. Women aged 16 years or older were eligible
for enrolment if they had a gram-stained endocer-
vical smear showing gram-negative diplococci
within polymorphonuclear leukocytes, a recent un-
treated culture positive for N. gonorrhoeae, or sexual
exposure to men with urethral gonorrhea within
the two weeks prior to enrollment. All patients had
to have positive cultures for N. gonorrhoeae at the
initial visit to be evaluated.
Women of childbearing age were required to use
a recognized contraceptive method during the
study period. Patients were excluded if they had
concomitant infection(s), such as complicated
gonococcal infection, or disease that would com-
promise treatment evaluation; were pregnant or
nursing; were known to have hypersensitivity to
quinolone or cephalosporin antibiotics; had re-
ceived antibiotics or any investigational drug
within two weeks of enrollment; needed concur-
rent antimicrobial medication other than topical or
antifungal agents; had received chronic treatment
with warfarin, diflunisal, fluconazole, or theophyl-
line; or had taken antacids or sucralfate within four
hours of dosing. Patients with recent positive cul-
tures for C. trachomatis were also excluded. The
study was approved by the institutional review
board at each participating center, and written in-
formed consent was obtained from all patients be-
fore enrolment.
Specimens for gram staining of N. gonorrhoeae
were obtained from the endocervix. Specimens for
culture of N. gonorrhoeae were obtained from the
cervix, pharynx, and rectum, and all patients had an
endocervical culture for C. trachomatis. Blood and
urine samples were taken for standard laboratory
tests and syphilis serology. In addition, all partici-
pants had a urine pregnancy test immediately be-
fore enrolment.
Patients were randomly assigned to receive ei-
ther a single oral dose of grepafloxacin (400 mg) or
cefiximc (400 rag) in an open study. The random-
ization schedule was based on a block design with
four patient numbers (two grepafloxacin and two
cefixime in each block). Each center assigned a
specific regimen to each patient, enrolling them in
the exact order specified on the list. Patients took
the medication under supervision and were in-
structed to attend a follow-up visit 5 to 10 days later
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for repeat examination and cultures. Participants
were advised to abstain from unprotected sexual
intercourse during the study.
Specimens for N. gonorrhoeae isolation were in-
oculated directly onto Thayer-Martin selective agar
and incubated for 24 to 48 hours at 36 C in a 5%
CO2 atmosphere. All presumptive gonococcal iso-
lates were confirmed by standard methods14 and
stored at-70 C in Trypticase soy broth containing
15% glycerol prior to antibiotic susceptibility test-
ing. The MICs for all isolates were determined by
agar dilution. 15 Isolates were considered resistant
to penicillin and tetracycline if MICs were ->2.0
mg/L and resistant to cefixime if the MIC was
>0.25 mg/L. Susceptibility to grepafloxacin was de-
termined based on a tentative resistant breakpoint
of >0.06 mg/L.6 All isolates were tested for 13-
lactamase production by the chromogenic cephalo-
sporin method.7 Specimens for the isolation of C.
trachomatis were inoculated into McCoy tissue cul-
ture cells and examined by indirect immunofluo-
rescence.
The primary measure of study drug efficacy was
microbiological response to therapy. Responses
were classified as eradication or persistence on the
basis of posttreatment cultures for N. gonorr/}oeae.
Overall tests of comparability between the two
treatment groups were conducted for several cat-
egorical variables by using Cochran-Mantel-
Haenszel statistics to adjust for the multicenter na-
ture of the trial. Confidence intervals (CIs) of 95%
for the differences between the two groups in mi-
crobiological response rates were calculated. A CI
that crossed zero and remained within -10% or
greater (for efficacy rates -> 90%) indicated treat-
ment equivalence, whereas a lower limit >0% in-
dicated grepafloxacin superiority.
RESULTS
A total of 380 women, ranging in age from 15; to 554
years (mean age 23.5 years), were enrolled in the
study (191 in the grepafloxacin group and 189 in
the cefixime group), including one 15-year old who
was enrolled by mistake. There were 332 black
patients (87%), 28 Caucasian, and 20 of other racial
origin. The patients enrolled in each treatment
group were similar with respect to age, race, smok-
ing habits, alcohol consumption, and illicit drug
use. However, endocervical infection with C. tra-
chomatis was more common among grepafloxacin-
TABLE I. Eradication of N. gonorrhoeae by site
of infection
Isolates eradicated/isolates tested (%)
Site of Grepafloxacin Cefixime
infection 400 mg 400 mg P-value
Cervix 114/I 15 (99. )b 124/I 25 (99.2) NS
Rectum 32/32 (100) 37/38 (97.4) NS
Pharynx 15/15 (100) 11/16 (68.8) 0.043
Overall 123/124 (99.2) 124/I 31 (94.7) 0.067
aDefined as a negative culture four or more days posttreatment from
bacteriologically evaluated patients. NS, not significant.
bGrepafloxacin equivalent to cefixime (95% CI, -9.75, 4. I%).
CDenotes eradication of N. gonorrhoeae from all anatomical sites; some
patients had infection at more than one site.
treated participants in that 31 of 191 women (16%)
in the grepafloxacin group and 18 of 189 women
(9.5%) in the cefixime group had C. trachomatis as
determined by a positive culture at enrolment (P
0.066).
Of the 380 patients enrolled in the study, 86 had
negative pretreatment cultures, 31 were lost to fol-
low-up, five withdrew consent, and three were con-
comitantly using additional antibiotics. Thus, 255
patients had positive initial N. gonorrhoeae cultures
and were available for microbiological evaluation at
follow-up. Approximately one third of patients
evaluated (80 of 255) with documented gonococcal
cervicitis also had involvement of the rectum and/
or pharynx; the efficacy of both treatment regimens
in eradicating N. gonorrhoeae from the various sites
is summarized in Table 1.
Endocervical infections were eradicated in 99%
ofwomen in each treatment group. All extragenital
infections treated with grepafloxacin (47 patients;
32 rectal and 15 pharyngeal infections) were cured,
while 3% (1 of 38) of rectal infections and 31% (5 of
16) of pharyngeal infections did not respond to ce-
fixime. When all infected sites are considered, 99%
of patients given grepafloxacin were microbiologi-
cally cured, compared with 95% of those treated
with cefixime. None of the eight patients with ap-
parent treatment failure (one given grepafloxacin,
seven given ccfixime) said they had had unpro-
tected sexual intercourse during the study period.
A total of 386 pretreatment isolates of N. gonor-
rhoeae were recovered from infected sites of 282
patients and tested for antibiotic susceptibility.
Thirty-seven percent (70 of 191) of the isolates
from grepafloxacin-treatcd patients and 27% (53 of
195) from cefixime-treated patients demonstrated
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TABLE 2. Eradication of penicillin- and tetracycline-resistant isolates of N. gonorrhoeae
Isolates eradicated/isolates tested (%)
Site of Grepafloxacin Cefixime
infection Isolate 400 mg 400 mg
Cervix Penicillin-resistant 26/27 (96.3) 25/26 (96.2)
Tetracycline-resistant 19/21 (90.5) 14/15 (93.3)
13-1actamase-producing I/I (100.0) 8/8 (100.0)
Pharynx Penicillin-resistant 9/9 (100.0) 0/I (0.0)
Tetracycline-resistant 3/3 (100.0) 0/I (0.0)
13-1actamase-producing 4/4 (I 00.0)
Rectum Penicillin-resistant 3/4 (75.0) 3/4 (75.0)
Tetracycline-resistant 6/6 (100.0) 5/6 (83.3)
13-1actamase-producing I/I (100.0) I/I (100.0)
alncludes all microbiologically evaluated patients with positive pretreatrnent cultures.
bl3-1actamase-producing strains are a subset of penicillin-resistant strains and are included in the latter category.
COne cefixime-treated patient with rectal gonorrhea who was not treated successfully had a Neisseria gonorrhoeae isolate resistant to both penicillin and
tetracycline.
resistance to either penicillin or tetracycline; 25 of
71 (35%) of penicillin-resistant gonococci.produced
[3-1actamase. Both regimens were equally effective
in eradicating penicillin- and tetracycline-resistant
isolates from the cervix (Table 2). All 12 resistant
isolates that caused pharyngeal infections in grepa-
floxaci recipients were eradicated, as were 9 of 10
rectal infections. However, cefixime failed to eradi-
cate either of the two pharyngeal infections as well
as two of the 10 rectal infections caused by resistant
gonococci. All of the pretreatment isolates were ini-
tially susceptible to grcpafloxacin (MIC -<0.06 mg/
L) and only one isolate, which was obtained from a
patient randomized to grepafloxacin, had reduced
susceptibility to cefixime (MIC > 0.25 rag/L).
Although not a primary goal of the study, an
interesting finding was that a total of 49 patients
had positive pretreatment cultures for C. trachoma-
tis. Of these patients, 27 of 31 (87%) given grepa-
floxaci and 4 of 18 (22%) given cefixime had nega-
tive cultures for C. trachomatis at follow-up (P <
0.001). All patients with a confirmed C. trachomatis
infection were treated with doxycycline. In all,
about half (55%) of the patients in each treatment
group who returned for follow-up examination
were given a course of doxycycline to cover C. tra-
chomatis. In some cases this was based on pretreat-
merit culture results, but other clinics routinely
treated all participants at follow-up. In addition,
13% of patients in each group received metronida-
zole for the treatment of trichomonal infection.
Adverse events that were considered treatment
related occurred in 49 patients (62 events) in the
grepafloxacin group and 28 patients (34 events) in
the cefixime group (P 0.010). All but nine of the
events were mild to moderate and resolved spon-
taneously. One patient in each group experienced
severe vaginal discharge (lcukorrhea), which was
considered to be drug related. One patient in the
cefixime group was treated for a C. trachomatis in-
fection, and another experienced headache and
chest pain. In the grepafloxacin-treated group, one
patient reported severe nausea and vomiting, and
another had severe abdominal pain and diarrhea.
The most frequently reported treatment-related
events arc presented in Table 3. Vaginitis was the
most common individual treatment-related prob-
lem in each group, although when all gastrointes-
tinal events were combined, they were more com-
mon overall. The overall incidence of treatment-
related adverse events was higher in grepafloxacin-
treated patients, but there was no significant
difference in the incidences of individual adverse
events between the treatment groups. In addition,
none of the changes in laboratory values were con-
sidered clinically relevant.
DISCUSSION
This study has shown that a single 400-mg oral
dose of grepafloxacin is at least as effective as the
same dose of cefixime for treatment of uncompli-
cated gonorrhea in women. Both drugs were highly
effective (99% cure rate) in eradicating N. gonor-
rhoeae from the cervix, despite the fact that a third
of the study patients were infected with penicillin-
or tetracycline-resistant strains. Sixty-six of 70
(94%) of such isolates were eradicated by grepa-
floxacin as were 47 of 53 (89%) by cefixime. All
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TABLE 3. Summary of most common
treatment-related adverse events
No. (%) of events reported
after treatment
Grepafloxacin Cefixime
Adverse event (N 191) (N 189) P-value
Vaginitis 12 (6.3) 7 (3.7) 0.347
Nausea 8 (4.2) 4 (2. I) 0.380
Vomiting 7 (3.7) 2 (I. I) 0.175
Leukorrhea 3 (I.6) 5 (2.6) 0.501
Pruritis 4 (2. I) 2 (I. I) 0.685
Diarrhea 4 (2. I) (0.5) 0.372
Taste alteration 4 (2. I) 0 0.123
No. of patients
with one or more
treatment-related
adverse event(s) 49 (25.7) 28 (I 4.8) 0.010
aEvents reported by more than 2% of patients in either treatment
group.
pharyngeal and rectal gonococcal infections treated
with grepafloxacin were microbiologically cured,
while cefixime failed to resolve five (of 16) pharyn-
geal and one (of 38) rectal infections. Cefixime
therefore appears to be unsatisfactory in eradicat-
ing N. gonorrhoeae from the pharynx. The 100%
cure rate of extragenital infections seen with the
use of grepafloxacin in this study was the same as
that found in our previous study of grepafloxacin in
the treatment of gonococcal urethritis in male pa-
tients. 13 Thus, grepafloxacin appears to be highly
effective in both genital and extragenital gonococ-
cal infections.
Both regimens were well tolerated, and the most
common treatment-related adverse events were
gastrointestinal in nature. Although treatment-
related adverse events occurred with a higher fre-
quency in the grepafloxacin group, no individual
adverse event occurred with a significantly differ-
ent frequency in either group.
Additional data was collected on the eradication
of C. trachomatis in patients who were coinfected
with this pathogen, although this was not a primary
objective of the study. Like other cephalosporin
antibiotics, 18 cefixime has little antichlamydial ac-
tivity and, in this study, failed to cure most coex-
isting C. trachomatis endocervical infections. Grepa-
floxaci is active in vitro against C. trachomatiss’ 18
and was more effective than cefixime in eradicating
this pathogen from patients who had positive cul-
tures at pretreatment (87% vs. 22%, P < 0.001).
This high rate of eradication is encouraging, but
most C. trachomatis studies have a longer follow-up
period, usually of four weeks. A single dose of
grepafloxacin might, therefore, only be suppres-
sive, and further follow-up of such cases may have
revealed relapses. None of the present quinolones
are effective as single-dose therapy for infections
caused by C. trachomatis, and only ofloxacin has
been approved for chlamydial urethritis and cervi-
citis.
As C. trachomatis is frequently present along with
N. gonorrhoeae in genital infections, an agent that is
effective in eliminating both pathogens would be a
significant advance over conventional therapy us-
ing two or more antibiotics. Grepafloxacin has
greater antigonococcal and antichlamydial activity
in vitro than standard agents, 7, 8 and is two to 16
times more active than ceftriaxone and ofloxacin
against susceptible, as well as penicillin- and tetra-
cycline-resistant strains of N. gonorrhoeae. 7 More-
over, its activity is considerably greater than that of
tetracycline against chlamydia, with some strains of
C. trachomatis being up to 128 times more sensitive
to grepafloxacin. 19 Such potency, together with a
highly bactericidal action on Chlamydia species in
vitro, may translate into good clinical efficacy.
18
These data, as well as our initial findings in non-
gonococcal urethritis and cervicitis clinical trials (in
preparation), suggest that grepafloxacin may be
useful as therapy for genital infections when both
pathogens are present. Consequently, grepafloxa-
cin is a promising new therapeutic agent for com-
mon STDs in both males and females.
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